With a market capitalization (market cap) of $1.21B — a measure of how much the company is worth — PROCEPT BioRobotics Corporation is the 2459th most valuable company in Healthcare as of August 19, 2026. Shares trade at $21.32, up +1.09% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Visit websiteAs of August 19, 2026, PROCEPT BioRobotics Corporation (PRCT) is worth $1.21B — this is its market capitalization, the total value of all its outstanding shares.
PROCEPT BioRobotics Corporation’s market cap is $1.21B, which ranks it #2459 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
PROCEPT BioRobotics Corporation (PRCT) shares trade at $21.32, up 1.09% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025